- Home
- INFU vs INZY Comparison
INFU vs INZY Comparison
Compare INFU & INZY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- INFU
- INZY
- Stock Information
- Founded
- INFU 2005
- INZY 2015
- Country
- INFU United States
- INZY United States
- Employees
- INFU N/A
- INZY N/A
- Industry
- INFU Medical/Dental Instruments
- INZY Biotechnology: Pharmaceutical Preparations
- Sector
- INFU Health Care
- INZY Health Care
- Exchange
- INFU Nasdaq
- INZY Nasdaq
- Market Cap
- INFU 189.2M
- INZY 188.2M
- IPO Year
- INFU N/A
- INZY 2020
- Fundamental
- Price
- INFU $8.10
- INZY $1.38
- Analyst Decision
- INFU
- INZY Strong Buy
- Analyst Count
- INFU 0
- INZY 8
- Target Price
- INFU N/A
- INZY $17.75
- AVG Volume (30 Days)
- INFU 64.4K
- INZY 677.5K
- Earning Date
- INFU 11-07-2024
- INZY 11-05-2024
- Dividend Yield
- INFU N/A
- INZY N/A
- EPS Growth
- INFU 60.96
- INZY N/A
- EPS
- INFU 0.07
- INZY N/A
- Revenue
- INFU $132,783,999.00
- INZY N/A
- Revenue This Year
- INFU $10.23
- INZY N/A
- Revenue Next Year
- INFU $8.80
- INZY N/A
- P/E Ratio
- INFU $112.70
- INZY N/A
- Revenue Growth
- INFU 8.17
- INZY N/A
- 52 Week Low
- INFU $5.74
- INZY $1.38
- 52 Week High
- INFU $10.03
- INZY $7.80
- Technical
- Relative Strength Index (RSI)
- INFU 47.89
- INZY 20.47
- Support Level
- INFU $7.42
- INZY $2.68
- Resistance Level
- INFU $8.42
- INZY $3.18
- Average True Range (ATR)
- INFU 0.35
- INZY 0.28
- MACD
- INFU -0.03
- INZY -0.15
- Stochastic Oscillator
- INFU 49.28
- INZY 0.00
About INFU InfuSystems Holdings Inc.
InfuSystems Holdings Inc is a health care service provider, facilitating outpatient care for durable medical equipment manufacturers and health care providers. INFU services are provided under a two-platform model. The first platform is Patient Services, providing the last-mile solution for clinic-to-home healthcare where the continuing treatment involves complex durable medical equipment and services. The Patient segment is comprised of Oncology, Pain Management and Wound Therapy businesses. The second platform, Device Solutions, supports the Patient Services platform and leverages strong service orientation to win incremental business from its direct payer clients. The Device segment is comprised of direct payer rentals, pump and consumable sales, and biomedical services and repair.
About INZY Inozyme Pharma Inc.
Inozyme Pharma Incclinical-stage rare disease biopharmaceutical company developing novel therapeutics for the treatment of diseases impacting the vasculature, soft tissue, and skeleton. The company is pursuing the development of therapeutics to address the underlying causes of these debilitating diseases. The company is focused on developing a novel therapy to treat the rare genetic diseases of ENPP1 and ABCC6 Deficiencies. The company product candidate, INZ-701, is a soluble, recombinant, genetically engineered, fusion protein that is designed to correct a defect in a pathway involving ENPP1 and ABCC6 Deficiencies.